Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature (Q43446049)

23 November 2017

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature (English)

1 reference

23 November 2017

2

Oberdan Leo

1 reference

23 November 2017

Tino F Schwarz

1

1 reference

PubMed ID

18653222

23 November 2017

language of work or name

English

0 references

publication date

24 July 2008

1 reference

23 November 2017

1 reference

23 November 2017

110

1 reference

23 November 2017

S1-10

1 reference

23 November 2017

3 Suppl 1

1 reference

The epidemiology of human papillomavirus infections

23 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Chapter 2: The burden of HPV-related cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Persistent Genital Human Papillomavirus Infection as a Risk Factor for Persistent Cervical Dysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Chapter 1: HPV in the etiology of human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

HPV: from infection to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Human papillomavirus 16 E7 protein is associated with the nuclear matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Human papillomavirus type 16 and 18 gene expression in cervical neoplasias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Immune responses to human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Delivering on the promise: HPV vaccines and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Chapter 11: HPV vaccines: commercial research & development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Maintenance of serological memory by polyclonal activation of human memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Antigen dependent and independent mechanisms that sustain serum antibody levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

A hepatitis B vaccine formulated with a novel adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

New hepatitis B vaccine formulated with an improved adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Glycoprotein D adjuvant herpes simplex virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.05.036

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2008.05.036

1 reference

23 November 2017

1 reference

PubMed ID

18653222